Assetmark, Inc Bei Gene, Ltd. Transaction History

Assetmark, Inc

$32.1 Billion
Q2 2024

A detailed history of Assetmark, Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Assetmark, Inc holds 18,608 shares of BGNE stock, worth $4.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

18,608

Previous 16,677 11.58%

Holding current value

$4.3 Million

Previous $2.61 Million 1.76%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$129.52 - $174.32 $250,103 - $336,611	1,931 Added 11.58%	18,608 $2.65 Million
Q1 2024 May 06, 2024	BUY	$141.8 - $181.47 $677,945 - $867,608	4,781 Added 40.19%	16,677 $2.61 Million
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $222,772 - $283,018	1,404 Added 13.38%	11,896 $2.15 Million
Q3 2023 Oct 27, 2023	BUY	$179.87 - $225.13 $172,855 - $216,349	961 Added 10.08%	10,492 $1.89 Million
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $162,966 - $243,836	914 Added 10.61%	9,531 $1.7 Million
Q1 2023 May 05, 2023	BUY	$215.53 - $274.5 $596,587 - $759,816	2,768 Added 47.32%	8,617 $1.86 Million
Q4 2022 Feb 10, 2023	BUY	$125.51 - $229.3 $34,013 - $62,140	271 Added 4.86%	5,849 $1.29 Million
Q3 2022 Nov 01, 2022	BUY	$131.8 - $202.24 $126,528 - $194,150	960 Added 20.79%	5,578 $752,000
Q2 2022 Aug 03, 2022	BUY	$121.11 - $216.05 $88,652 - $158,148	732 Added 18.84%	4,618 $747,000
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $327,911 - $603,275	2,238 Added 135.8%	3,886 $733,000
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $338,041 - $529,502	1,360 Added 472.22%	1,648 $446,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $14,476 - $23,382	58 Added 25.22%	288 $105,000
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $292 - $367	1 Added 0.44%	230 $79,000
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $9,122 - $13,374	35 Added 18.04%	229 $80,000
Q4 2020 Feb 10, 2021	BUY	$221.31 - $316.61 $2,434 - $3,482	11 Added 6.01%	194 $50,000
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $5,107 - $7,733	27 Added 17.31%	183 $52,000
Q2 2020 Aug 11, 2020	BUY	$123.9 - $195.41 $247 - $390	2 Added 1.3%	156 $29,000
Q1 2020 May 12, 2020	BUY	$121.84 - $173.19 $365 - $519	3 Added 1.99%	154 $19,000
Q4 2019 Feb 11, 2020	SELL	$115.78 - $208.34 $810 - $1,458	-7 Reduced 4.43%	151 $25,000
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $113 - $146	1 Added 0.64%	158 $20,000
Q1 2019 May 14, 2019	BUY	$122.82 - $151.83 $19,282 - $23,837	157 New	157 $21,000

Others Institutions Holding BGNE

# of Institutions

212

Shares Held

45.1M

Call Options Held

106K

Put Options Held

93.1K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $24B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account